Overview
Sweden biopharmaceutical tools provider's Q4 sales grew 44% yr/yr but missed expectations
EBITDA margin strong despite currency headwinds
Company completed important antibody conjugation project
Outlook
Company sees increased customer activity in key markets as a positive indicator
Result Drivers
LARGE ORDER - Q4 sales included a significant order from a global pharmaceutical company, contributing to 44% sales growth
CURRENCY IMPACT - Strengthening of Swedish krona negatively affected EBITDA by SEK 1,027 thousand
ANTIBODY PROJECT - Completed a major antibody conjugation project, meeting customer expectations under time pressure
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Miss
SEK 40.25 mln
SEK 42.50 mln (2 Analysts)
Q4 EPS
SEK 0.10
Q4 EBITDA
SEK 11.74 mln
Q4 Operating Cash Flow
SEK 15.90 mln
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Genovis AB is SEK30.00, about 52.1% above its February 11 closing price of SEK19.72
The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 39 three months ago
Press Release: ID:nMFN7XjJ1D
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
